<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>EVAMIST - estradiol spray, metered </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Evamist safely and effectively. See full prescribing information for Evamist. 
Evamist (estradiol transdermal spray) 
Initial U.S. Approval: 1975 
</div>
<div class="Warning"><div>
<a name="i6edf9cd4-6eef-4f4f-872a-48b3a754b25d"></a><table border="0" cellpadding="3" cellspacing="1"><tbody class="Headless">
<tr class="First"><td><br></td></tr>
<tr class="Last"><td>
<h1 class="Warning"><span class="Bold">WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR 
DISORDERS, BREAST CANCER, AND PROBABLE <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span></span></h1>
<h1 class="Warning">
<span>See full prescribing information for complete boxed 
warning</span>.</h1>
<ul>
<li><span class="Bold">There is an increased risk of endometrial cancer in women 
with a uterus who use unopposed estrogens (<a href="#s13">5.2</a>)</span></li>
<li><span class="Bold">Women's Health Initiative substudies reported increased 
risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, invasive breast 
cancer, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (<a href="#s68">14.4</a>, 
<a href="#s69">14.5</a>)</span></li>
<li><span class="Bold">Estrogens with or without progestins should not be used for 
the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (<a href="#s9">5.1</a>, <a href="#s17">5.3</a>)</span></li>
<li><span class="Bold">Use estrogens with or without progestins at the lowest dose 
and for the shortest duration consistent with treatment goals and individual 
risks (<a href="#s3">2</a>)</span></li>
</ul>
</td></tr>
</tbody></table>
</div></div>
<div></div>
<div class="Warning"><div>
<a name="i6edf9cd4-6eef-4f4f-872a-48b3a754b25d"></a><table border="0" cellpadding="3" cellspacing="1"><tbody class="Headless">
<tr class="First"><td><br></td></tr>
<tr class="Last"><td>
<h1 class="Warning"><span class="Bold">WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR 
DISORDERS, BREAST CANCER, AND PROBABLE <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span></span></h1>
<h1 class="Warning">
<span>See full prescribing information for complete boxed 
warning</span>.</h1>
<ul>
<li><span class="Bold">There is an increased risk of endometrial cancer in women 
with a uterus who use unopposed estrogens (<a href="#s13">5.2</a>)</span></li>
<li><span class="Bold">Women's Health Initiative substudies reported increased 
risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, invasive breast 
cancer, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (<a href="#s68">14.4</a>, 
<a href="#s69">14.5</a>)</span></li>
<li><span class="Bold">Estrogens with or without progestins should not be used for 
the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (<a href="#s9">5.1</a>, <a href="#s17">5.3</a>)</span></li>
<li><span class="Bold">Use estrogens with or without progestins at the lowest dose 
and for the shortest duration consistent with treatment goals and individual 
risks (<a href="#s3">2</a>)</span></li>
</ul>
</td></tr>
</tbody></table>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Evamist is an estrogen indicated for the treatment of moderate to 
severe vasomotor symptoms due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> (<a href="#s2">1</a>) </p>
<br>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>One spray once daily to forearm as a starting dose (<a href="#s5">2.2</a>) 
</li>
<li>Increase to two or three sprays daily to forearm based upon clinical 
response (<a href="#s5">2.2</a>) </li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>One spray delivers 90 mcL that contains 1.53 mg estradiol </li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Undiagnosed abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<a href="#s7">4</a>) </li>
<li>Known, suspected, or history of cancer of the breast (<a href="#s7">4</a>, 
<a href="#s13">5.2</a>) </li>
<li>Known or suspected estrogen-dependent neoplasia (<a href="#s7">4</a>, <a href="#s13">5.2</a>) </li>
<li>Active <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, or history of these 
conditions (<a href="#s7">4</a>, <a href="#s9">5.1</a>) </li>
<li>Active or recent (within the past year) arterial thromboembolic disease (for 
example, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>) (<a href="#s7">4</a>, <a href="#s9">5.1</a>) </li>
<li>Known liver dysfunction or disease (<a href="#s7">4</a>, <a href="#s23">5.9</a>) </li>
<li>Known or suspected pregnancy (<a href="#s7">4</a>, <a href="#s48">8.1</a>) </li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>An increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, 
<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> has been reported with the use of 
estrogens with or without progestins (<a href="#s9">5.1</a>, <a href="#s17">5.3</a>) </li>
<li>An increased risk of invasive breast cancer has been reported with the use 
of estrogens plus progestins (<a href="#s13">5.2</a>) </li>
<li>Estrogens increase the risk of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> (<a href="#s18">5.4</a>) 
</li>
<li>Discontinue estrogens if severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, severe 
<span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> or <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> occurs (<a href="#s19">5.5</a>, <a href="#s20">5.6</a>, <a href="#s23">5.9</a>, <a href="#s24">5.10</a>) </li>
<li>Monitor thyroid function in women on thyroid hormone replacement therapy (<a href="#s25">5.11</a>, <a href="#s33">5.19</a>) </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (≥5%) are: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, breast 
<span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> and <span class="product-label-link" type="condition" conceptid="4021485" conceptname="Nipple tenderness">nipple pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, and <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span> (<a href="#s35">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Ther-Rx 
Corporation at 1-877-567-7676 or FDA at 1-800-FDA-1088 or </span><span>www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul><li>Estrogen products may interact with inducers and inhibitors of CYP3A4 (<a href="#s46">7.1</a>) </li></ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Nursing Mothers: Estrogen administration to nursing mothers has been shown 
to decrease the quantity and quality of the breast milk (<a href="#s49">8.3</a>) 
</li>
<li>Geriatric Use: An increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in women over 70 years 
of age was reported in the two substudies of the Women's Health Initiative 
Memory Study (<a href="#s51">8.5</a>) </li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 8/2010</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 General Dosing Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Treatment of Moderate to Severe Vasomotor Symptoms</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Malignant Neoplasms</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder Disease</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Visual Abnormalities</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Addition of a Progestin When a Woman Has Not Had a Hysterectomy</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Elevated Blood Pressure</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10 <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">Impaired Liver Function</span> and Past History of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic Jaundice</span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11 <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span></a></h2>
<h2><a href="#section-5.12" class="toc">5.12 <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></a></h2>
<h2><a href="#section-5.13" class="toc">5.13 <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></a></h2>
<h2><a href="#section-5.14" class="toc">5.14 Exacerbation of <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">Endometriosis</span></a></h2>
<h2><a href="#section-5.15" class="toc">5.15 Exacerbation of Other Conditions</a></h2>
<h2><a href="#section-5.16" class="toc">5.16 Alcohol-Based Products are Flammable</a></h2>
<h2><a href="#section-5.17" class="toc">5.17 Application of Sunscreen</a></h2>
<h2><a href="#section-5.18" class="toc">5.18 Laboratory Tests</a></h2>
<h2><a href="#section-5.19" class="toc">5.19 Drug and Laboratory Test Interactions</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Study Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Additional Adverse Reactions Reported With Estrogen and/or Progestin Therapy</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Metabolic Interactions</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Effects on Vasomotor Symptoms</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Effect of Application Site Washing</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Potential for Estradiol Transfer</a></h2>
<h2><a href="#section-13.4" class="toc">14.4 Women's Health Initiative Studies</a></h2>
<h2><a href="#section-13.5" class="toc">14.5 Women's Health Initiative Memory Study</a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Bleeding</span></a></h2>
<h2><a href="#section-16.2" class="toc">17.2 Common Adverse Reactions with Estrogen</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BWS"></a><a name="section-1"></a><p></p>
<a href="http://"></a>WARNING -- ENDOMETRIAL CANCER, CARDIOVASCULAR AND OTHER RISKS<p class="First"><span class="Bold">ENDOMETRIAL CANCER</span></p>
<p>Adequate diagnostic measures, including endometrial sampling when indicated, 
should be undertaken to rule out malignancy in all cases of undiagnosed 
persistent or recurring abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> <span class="Italics">[see 
Warnings and Precautions (<a href="#s13">5.2</a>)]</span>.</p>
<p><span class="Bold">CARDIOVASCULAR AND OTHER RISKS</span></p>
<p>Estrogens with or without progestins should not be used for the prevention of 
cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> <span class="Italics">[see Warnings and 
Precautions (<a href="#s9">5.1</a>) and (<a href="#s17">5.3</a>) and Clinical 
Studies (14.4 and 14.5)]</span>.</p>
<p>The Women's Health Initiative (WHI) estrogen alone substudy reported 
increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) in postmenopausal women 
(50 to 79 years of age) during 6.8 years and 7.1 years, respectively, of 
treatment with daily oral conjugated estrogens (CE 0.625 mg), relative to 
placebo <span class="Italics">[see Warnings and Precautions (<a href="#s9">5.1</a>) and Clinical Studies (<a href="#s68">14.4</a>)].</span></p>
<p>The estrogen plus progestin WHI substudy reported increased risk of 
<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, invasive breast cancer, pulmonary emboli, and DVT 
in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment 
with daily oral CE 0.625 mg combined with medroxyprogesterone acetate (MPA 2.5 
mg), relative to placebo <span class="Italics">[see Warnings and Precautions (<a href="#s9">5.1</a>) and (<a href="#s13">5.2</a>) and Clinical Studies (<a href="#s68">14.4</a>)]</span>.</p>
<p>The Women's Health Initiative Memory Study (WHIMS), a substudy of the WHI, 
reported increased risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 
65 years of age or older during 5.2 years of treatment with daily CE 0.625 mg 
alone and during 4 years of treatment with daily CE 0.625 mg combined with MPA 
2.5 mg, relative to placebo. It is unknown whether this finding applies to 
younger postmenopausal women <span class="Italics">[see Warnings and Precautions 
(<a href="#s17">5.3</a>), Use in Specific Populations (<a href="#s51">8.5</a>) 
and Clinical Studies (<a href="#s69">14.5</a>)]</span>.</p>
<p>In the absence of comparable data, these risks should be assumed to be 
similar for other doses of CE and MPA and other combinations and dosage forms of 
estrogens and progestins. Because of these risks, estrogens with or without 
progestins should be prescribed at the lowest effective doses and for the 
shortest duration consistent with treatment goals and risks for the individual 
woman.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Evamist (estradiol transdermal spray) is an estrogen indicated for the treatment 
of moderate to severe vasomotor symptoms due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<h2>2.1 General Dosing Information</h2>
<p class="First">When estrogen is prescribed for a postmenopausal woman with a 
uterus, generally, a progestin should also be initiated to reduce the risk of 
endometrial cancer. A woman without a uterus does not need progestin.</p>
<p>Use of estrogen, alone or in combination with a progestin, should be with the 
lowest effective dose and for the shortest duration consistent with treatment 
goals and risks for the individual woman. Postmenopausal women should be 
re-evaluated periodically as clinically appropriate (for example at 3-month to 
6-month intervals) to determine if treatment is still necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2"></a><p></p>
<h2>2.2 Treatment of Moderate to Severe Vasomotor Symptoms</h2>
<p class="First">Evamist therapy should be initiated with one spray per day. 
Dosage adjustment should be guided by the clinical response.</p>
<p>Before applying the first dose from a new applicator, the pump should be 
primed by spraying 3 sprays with the cover on. The container should be held 
upright and vertical for spraying.</p>
<p>One, two or three sprays are applied each morning to adjacent, 
non-overlapping areas on the inner surface of the forearm, starting near the 
elbow. Sprays should be allowed to dry for approximately 2 minutes and the site 
should not be washed for 30 minutes. Application of Evamist to other skin 
surfaces has not been adequately studied. Evamist should not be applied to skin 
surfaces other than the forearm.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Evamist is an estradiol transdermal spray. One spray delivers 90 mcL that 
contains 1.53 mg of estradiol.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Evamist should not be used in women with any of the following 
conditions:</p>
<ul>
<li>Undiagnosed abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> </li>
<li>Known, suspected, or history of cancer of the breast </li>
<li>Known or suspected estrogen-dependent neoplasia </li>
<li>Active <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, or history of these 
conditions </li>
<li>Active or recent (within the past year) arterial thromboembolic disease (for 
example, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>) </li>
<li>Known liver dysfunction or disease </li>
<li>Known or suspected pregnancy </li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span></h2>
<p class="First">An increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) has 
been reported with estrogen alone therapy. An increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, DVT, 
<span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> has been reported with estrogen 
plus progestin therapy. Should any of these occur or be suspected, estrogens 
with or without progestins should be discontinued immediately.</p>
<p>Risk factors for arterial vascular disease (for example, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, 
<span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, tobacco use, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, and <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>) and/or venous 
<span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> (for example, personal history or family history of venous 
<span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> [VTE], <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, and <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>) should be 
managed appropriately.</p>
<a href="http://"></a><a href="http://"></a><p><span class="Italics"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></span></p>
<p>In the Women's Health Initiative (WHI) estrogen alone substudy, a 
statistically significant increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was reported in women 
receiving daily conjugated estrogens (CE 0.625 mg) compared to placebo (45 
versus 33 per 10,000 women-years). The increase in risk was demonstrated in year 
1 and persisted<span class="Sup">1</span><span class="Italics">[see Clinical Studies 
(<a href="#s68">14.4</a>)]</span>.</p>
<p>In the estrogen plus progestin substudy of WHI, a statistically significant 
increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was reported in women receiving daily CE 0.625 mg plus 
medroxyprogesterone acetate (MPA 2.5 mg) compared to placebo (31 versus 24 per 
10,000 women-years). The increase in risk was demonstrated after the first year 
and persisted <span class="Italics">[see Clinical Studies (<a href="#s68">14.4</a>)]</span>.</p>
<a href="http://"></a><a href="http://"></a><p><span class="Italics">Coronary heart disease</span></p>
<p>In the estrogen alone substudy of WHI, no overall effect on coronary heart 
disease (CHD) events (defined as non-fatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> [MI], silent 
MI, or CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) was reported in women receiving estrogen alone compared to 
placebo<span class="Sup">2</span><span class="Italics">[see Clinical Studies (<a href="#s68">14.4</a>)]</span>.</p>
<p>In the estrogen plus progestin substudy of the WHI, no statistically 
significant increase of CHD events was reported in women receiving CE/MPA 
compared to women receiving placebo (39 versus 33 per 10,000 women-years). An 
increase in relative risk was demonstrated in year 1, and a trend toward 
decreasing relative risk was reported in years 2 through 5 <span class="Italics">[see Clinical Studies (<a href="#s68">14.4</a>)]</span>.</p>
<p>In postmenopausal women with documented heart disease (n = 2,763, average age 
66.7 years), in a controlled clinical trial of secondary prevention of 
cardiovascular disease (Heart and Estrogen/Progestin Replacement Study [HERS]), 
treatment with daily CE 0.625 mg/MPA 2.5 mg demonstrated no cardiovascular 
benefit. During an average follow-up of 4.1 years, treatment with CE/MPA did not 
reduce the overall rate of CHD events in postmenopausal women with established 
coronary heart disease. There were more CHD events in the CE/MPA-treated group 
than in the placebo group in year 1, but not during the subsequent years. Two 
thousand, three hundred and twenty-one (<a href="#s3">2</a>,321) women from the 
original HERS trial agreed to participate in an open label extension of HERS, 
HERS II. Average follow-up in HERS II was an additional 2.7 years, for a total 
of 6.8 years overall. Rates of CHD events were comparable among women in the 
CE/MPA group and the placebo group in HERS, HERS II, and overall.</p>
<a href="http://"></a><a href="http://"></a><p><span class="Italics"><span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous Thromboembolism</span> (VTE)</span></p>
<p>In the estrogen alone substudy of WHI, the risk of VTE (DVT and pulmonary 
<span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> [PE]) was reported to be increased for women receiving daily CE 
compared to placebo (30 versus 22 per 10,000 women-years), although only the 
increased risk of DVT reached statistical significance (23 versus 15 per 10,000 
women-years). The increase in VTE risk was demonstrated during the first two 
years<span class="Sup">3</span><span class="Italics">[see Clinical Studies (<a href="#s68">14.4</a>)]</span>.</p>
<p>In the estrogen plus progestin substudy of WHI, a statistically significant 
two-fold greater rate of VTE was reported in women receiving daily CE/MPA 
compared to women receiving placebo (35 versus 17 per 10,000 women-years). 
Statistically significant increases in risk for both DVT (26 versus 13 per 
10,000 women-years) and PE (18 versus 8 per 10,000 women-years) were also 
demonstrated. The increase in VTE risk was observed during the first year and 
persisted <span class="Italics">[see Clinical Studies (<a href="#s68">14.4</a>)]</span>.</p>
<p>If feasible, estrogens should be discontinued at least 4 to 6 weeks before 
surgery of the type associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, or 
during periods of prolonged immobilization.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2>5.2 Malignant Neoplasms</h2>
<p class="First"><span class="Italics">Endometrial Cancer</span></p>
<p>An increased risk of endometrial cancer has been reported with the use of 
unopposed estrogen therapy in women with a uterus. The reported endometrial 
cancer risk among unopposed estrogen users is about 2 to 12 times greater than 
in nonusers, and appears dependent on duration of treatment and on estrogen 
dose. Most studies show no significant increased risk associated with use of 
estrogens for less than 1 year. The greatest risk appears associated with 
prolonged use, with an increased risk of 15- to 24-fold for 5 to 10 years or 
more. This risk has been shown to persist for at least 8 to 15 years after 
estrogen therapy is discontinued.</p>
<p>Clinical surveillance of all women using estrogen plus progestin therapy is 
important. Adequate diagnostic measures, including endometrial sampling when 
indicated, should be undertaken to rule out malignancy in all cases of 
undiagnosed persistent or recurring abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>. There is no 
evidence that the use of natural estrogens results in a different endometrial 
risk profile than synthetic estrogens of equivalent estrogen dose. Adding a 
progestin to estrogen therapy has been shown to reduce the risk of endometrial 
<span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, which may be a precursor to endometrial cancer.</p>
<a href="http://"></a><a href="http://"></a><p><span class="Italics">Breast Cancer</span></p>
<p>The most important randomized clinical trial providing information about this 
issue in estrogen alone users is the Women's Health Initiative (WHI) substudy of 
daily conjugated estrogens (CE 0.625 mg). In the estrogen alone substudy of WHI, 
after an average of 7.1 years of follow-up, daily CE 0.625 mg was not associated 
with an increased risk of invasive breast cancer (relative risk [RR] 0.80, 95 
percent nominal confidence interval [nCI] 0.62-1.04) <span class="Italics">[see 
Clinical Studies (<a href="#s68">14.4</a>)].</span></p>
<p>The most important randomized clinical trial providing information about this 
issue in estrogen plus progestin users is the Women's Health Initiative (WHI) 
substudy of daily CE 0.625 mg plus medroxyprogesterone acetate (MPA 2.5 mg). In 
the estrogen plus progestin substudy, after a mean follow-up of 5.6 years, the 
WHI substudy reported an increased risk of breast cancer in women who took daily 
CE/MPA. In this substudy, prior use of estrogen alone or estrogen plus progestin 
therapy was reported by 26 percent of the women. The relative risk of invasive 
breast cancer was 1.24 (95 percent nCI 1.01-1.54), and the absolute risk was 41 
versus 33 cases per 10,000 women-years, for estrogen plus progestin compared 
with placebo, respectively. Among women who reported prior use of hormone 
therapy, the relative risk of invasive breast cancer was 1.86, and the absolute 
risk was 46 versus 25 cases per 10,000 women-years, for estrogen plus progestin 
compared with placebo. Among women who reported no prior use of hormone therapy, 
the relative risk of invasive breast cancer was 1.09, and the absolute risk was 
40 versus 36 cases per 10,000 women-years for estrogen plus progestin compared 
with placebo. In the same substudy, invasive breast cancers were larger and 
diagnosed at a more advanced stage in the CE/MPA group compared with the placebo 
group. <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">Metastatic disease</span> was rare, with no apparent difference between the two 
groups. Other prognostic factors, such as histologic subtype, grade and hormone 
receptor status did not differ between the groups <span class="Italics">[see 
Clinical Studies (<a href="#s68">14.4</a>)].</span></p>
<p>Observational studies have also reported an increased risk of breast cancer 
for estrogen plus progestin therapy, and a smaller increased risk for estrogen 
alone therapy, after several years of use. The risk increased with duration of 
use, and appeared to return to baseline over about 5 years after stopping 
treatment (only the observational studies have substantial data on risk after 
stopping). Observational studies also suggest that the risk of breast cancer was 
greater, and became apparent earlier, with estrogen plus progestin therapy as 
compared to estrogen alone therapy. However, these studies have not found 
significant variation in the risk of breast cancer among different estrogens or 
among different estrogen plus progestin combinations, doses, or routes of 
administration.</p>
<p>The use of estrogen alone and estrogen plus progestin has been reported to 
result in an increase in abnormal mammograms requiring further evaluation.</p>
<p>All women should receive yearly breast examinations by a healthcare provider 
and perform monthly breast self-examinations. In addition, mammography 
examinations should be scheduled based on patient age, risk factors, and prior 
mammogram results.</p>
<a href="http://"></a><a href="http://"></a><p><span class="Italics">Ovarian Cancer</span></p>
<p>The estrogen plus progestin substudy of the WHI reported that daily CE/MPA 
increased the risk of ovarian cancer. After an average follow-up of 5.6 years, 
the relative risk for ovarian cancer for CE/MPA versus placebo was 1.58 (95 
percent nCI, 0.77-3.24) but was not statistically significant. The absolute risk 
for CE/MPA vs. placebo was 4.2 versus 2.7 cases per 10,000 women-years. In some 
epidemiologic studies, the use of estrogen-only products, in particular for 10 
or more years, has been associated with an increased risk of ovarian cancer. 
Other epidemiologic studies have not found these associations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></h2>
<p class="First">In the estrogen alone Women's Health Initiative Memory Study 
(WHIMS), a substudy of the WHI, a population of 2,947 hysterectomized women 65 
to 79 years of age was randomized to daily conjugated estrogens (CE 0.625 mg) or 
placebo. In the estrogen plus progestin WHIMS substudy, a population of 4,532 
postmenopausal women 65 to 79 years of age was randomized to daily CE 0.625 mg 
plus medroxyprogesterone acetate (MPA 2.5 mg) or placebo.</p>
<p>In the estrogen alone substudy, after an average follow-up of 5.2 years, 28 
women in the CE alone group and 19 women in the placebo group were diagnosed 
with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE alone 
versus placebo was 1.49 (95 percent CI, 0.83-2.66). The absolute risk of 
probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE alone versus placebo was 37 versus 25 cases per 10,000 
women-years <span class="Italics">[see Use in Specific Populations (<a href="#s51">8.5</a>) and Clinical Studies (<a href="#s69">14.5</a>)]</span>.</p>
<p>In the estrogen plus progestin substudy, after an average follow-up of 4 
years, 40 women in the CE/MPA group and 21 women in the placebo group were 
diagnosed with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for 
CE/MPA versus placebo was 2.05 (95 percent CI, 1.21-3.48). The absolute risk of 
probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE/MPA versus placebo was 45 versus 22 cases per 10,000 
women-years <span class="Italics">[see Use in Specific Populations (<a href="#s51">8.5</a>) and Clinical Studies (<a href="#s69">14.5</a>)]</span>.</p>
<p>When data from the two populations were pooled as planned in the WHIMS 
protocol, the reported overall relative risk for probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> was 1.76 (95 
percent CI, 1.19-2.60). Since both substudies were conducted in women 65 to 79 
years of age, it is unknown whether these findings apply to younger 
postmenopausal women <span class="Italics">[see Use in Specific Populations (<a href="#s51">8.5</a>) and Clinical Studies (<a href="#s69">14.5</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder Disease</span></h2>
<p class="First">A two- to four-fold increase in the risk of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> requiring 
surgery in postmenopausal women receiving estrogens has been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></h2>
<p class="First">Estrogen administration may lead to severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> in women with breast 
cancer and bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>. If <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> occurs, use of the drug should be 
stopped and appropriate measures taken to reduce the serum calcium level.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.6"></a><p></p>
<h2>5.6 Visual Abnormalities</h2>
<p class="First">Retinal vascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> has been reported in women receiving estrogens. 
Discontinue medication pending examination if there is sudden partial or 
complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, or a sudden onset of <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">proptosis</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, or <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>. 
If examination reveals <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> or retinal vascular lesions, estrogens should 
be permanently discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.7"></a><p></p>
<h2>5.7 Addition of a Progestin When a Woman Has Not Had a Hysterectomy</h2>
<p class="First">Studies of the addition of a progestin for 10 or more days of a 
cycle of estrogen administration, or daily with estrogen in a continuous 
regimen, have reported a lowered incidence of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> than would 
be induced by estrogen treatment alone. <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">Endometrial hyperplasia</span> may be a 
precursor to endometrial cancer.</p>
<p>There are, however, possible risks that may be associated with the use of 
progestins with estrogens compared to estrogen alone regimens. These include a 
possible increased risk of breast cancer, adverse effects on lipoprotein 
metabolism (lowering HDL, raising LDL), and impairment of glucose tolerance.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.8"></a><p></p>
<h2>5.8 Elevated Blood Pressure</h2>
<p class="First">In a small number of case reports, substantial increases in blood pressure have 
been attributed to idiosyncratic reactions to estrogens. In a large, randomized, 
placebo-controlled clinical trial, a generalized effect of estrogens on blood 
pressure was not seen. Blood pressure should be monitored at regular intervals 
with estrogen use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.9"></a><p></p>
<h2>5.9 <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span></h2>
<p class="First">In women with preexisting <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, estrogen therapy may be 
associated with elevations of plasma triglycerides leading to <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> and 
other complications. Consider discontinuation of treatment if <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> or 
other complications develop.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.10"></a><p></p>
<h2>5.10 <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">Impaired Liver Function</span> and Past History of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic Jaundice</span></h2>
<p class="First">Estrogens may be poorly metabolized in women with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span>. For 
women with a history of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> associated with past estrogen use 
or with pregnancy, caution should be exercised, and in the case of recurrence, 
medication should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.11"></a><p></p>
<h2>5.11 <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span></h2>
<p class="First">Estrogen administration leads to increased thyroid-binding globulin (TBG) 
levels. Women with <span class="product-label-link" type="condition" conceptid="4193309" conceptname="Thyroid function tests normal">normal thyroid function</span> can compensate for the increased TBG 
by making more thyroid hormone, thus maintaining free T<span class="Sub">4</span> 
and T<span class="Sub">3</span> serum concentrations in the normal range. Women 
dependent on thyroid hormone replacement therapy who are also receiving 
estrogens may require increased doses of their thyroid hormone replacement 
therapy. These women should have their thyroid function monitored in order to 
maintain their free thyroid hormone levels in an acceptable range.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.12"></a><p></p>
<h2>5.12 <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></h2>
<p class="First">Estrogens may cause some degree of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>. Women who have conditions 
that might be influenced by this factor, such as a cardiac or renal dysfunction, 
warrant careful observation when estrogens are prescribed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.13"></a><p></p>
<h2>5.13 <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></h2>
<p class="First">Estrogens should be used with caution in women with preexisting severe 
<span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.14"></a><p></p>
<h2>5.14 Exacerbation of <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">Endometriosis</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">Endometriosis</span> may be exacerbated with administration of estrogens. A few cases 
of malignant transformation of residual endometrial implants have been reported 
in women treated post-hysterectomy with estrogen alone therapy. For women known 
to have residual <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span> post-hysterectomy, the addition of progestin 
should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.15"></a><p></p>
<h2>5.15 Exacerbation of Other Conditions</h2>
<p class="First">Estrogens may cause an <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, 
<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>, <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> and hepatic <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span> and 
should be used with caution in women with these conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.16"></a><p></p>
<h2>5.16 Alcohol-Based Products are Flammable</h2>
<p class="First">Avoid fire, flame or smoking until the spray has dried.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.17"></a><p></p>
<h2>5.17 Application of Sunscreen</h2>
<p class="First">When sunscreen is applied approximately one hour after application of Evamist, 
estradiol absorption was decreased by 11 percent. When sunscreen is applied 
approximately one hour before the application of Evamist, no significant change 
in estradiol absorption was observed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.18"></a><p></p>
<h2>5.18 Laboratory Tests</h2>
<p class="First">Serum follicle stimulating hormone and estradiol levels have not been shown to 
be useful in the management of moderate to severe vasomotor symptoms.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.19"></a><p></p>
<h2>5.19 Drug and Laboratory Test Interactions</h2>
<p class="First">Accelerated <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, partial thromboplastin time, and 
platelet aggregation time; increased platelet count; increased factors II, VII 
antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, 
II-VII-X complex, and beta- thromboglobulin; decreased levels of antifactor Xa 
and antithrombin III, decreased antithrombin III activity; increased levels of 
fibrinogen and fibrinogen activity; increased <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> antigen and 
activity.</p>
<p>Increased TBG levels leading to increased circulating total thyroid hormone 
levels, as measured by protein-bound iodine (PBI), T<span class="Sub">4</span> 
levels (by column or by radioimmunoassay) or T<span class="Sub">3</span> levels by 
radioimmunoassay. T<span class="Sub">3</span> resin uptake is decreased, 
reflecting the elevated TBG. Free T<span class="Sub">4</span> and free T<span class="Sub">3</span> concentrations are unaltered. Women on thyroid hormone 
replacement therapy may require higher doses of thyroid hormone.</p>
<p>Other binding proteins may be elevated in serum (corticosteroid binding 
globulin [CBG], SHBG), leading to increased total circulating corticosteroids 
and sex steroids, respectively. Free hormone concentrations, such as 
testosterone and estradiol, may be decreased. As with other transdermal 
estradiol products, a slight increase in SHBG was seen with Evamist active drug 
compared with baseline.</p>
<p>Increased plasma HDL and HDL<span class="Sub">2</span> <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> subfraction 
concentrations, reduced LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> concentration, increased triglyceride 
levels.</p>
<p>Impaired glucose tolerance.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Study Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying 
conditions, adverse reaction rates observed in the clinical trials of a drug 
cannot be directly compared to rates in the clinical trials of another drug and 
may not reflect the rates observed in practice.</p>
<p>In a 12-week, randomized, placebo-controlled trial of Evamist in 454 women, 
80-90 percent of women randomized to active drug received at least 70 days of 
therapy and 75-85 percent randomized to placebo received at least 70 days of 
therapy.</p>
<p>The adverse reactions that occurred in at least 5 percent of women in any 
treatment group are shown in <a href="#t1">Table 1</a>.</p>
<a href="http://"></a><a name="ib06f5e91-ac41-465b-8efc-d68d5f092092"></a><table width="100%">
<caption><span>Table 1. Frequency of Adverse Reactions (≥ 5%) in Any Treatment Group 
in a Controlled Study of Evamist</span></caption>
<col align="left" width="21%">
<col align="left" width="12%">
<col align="left" width="13%">
<col align="left" width="13%">
<col align="left" width="12%">
<col align="left" width="12%">
<col align="left" width="13%">
<thead><tr class="First Last">
<th align="left"><br></th>
<th align="left" colspan="1"><br></th>
<th align="left" colspan="3">Frequency n (%) </th>
<th align="left" colspan="2"><br></th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left"><span class="Bold">System Organ Class <br>Preferred Term</span></td>
<td align="left"><span class="Bold">1 
Spray</span></td>
<td align="left"><span class="Bold">2 
Sprays</span></td>
<td align="left"><span class="Bold">3 
Sprays</span></td>
</tr>
<tr>
<td align="left">Placebo <br>(N = 77) </td>
<td align="left">Evamist <br>(N = 76) </td>
<td align="left">Placebo <br>(N = 76) </td>
<td align="left">Evamist <br>(N = 74) </td>
<td align="left">Placebo <br>(N = 75) </td>
<td align="left">Evamist <br>(N = 76) </td>
</tr>
<tr><td align="left"><span class="Bold">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span></span></td></tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">Breast tenderness</span> </td>
<td align="left">0 (0) </td>
<td align="left">4 (5) </td>
<td align="left">4 (5) </td>
<td align="left">5 (7) </td>
<td align="left">0 (0) </td>
<td align="left">4 (5) </td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4021485" conceptname="Nipple tenderness">Nipple pain</span> </td>
<td align="left">0 (0) </td>
<td align="left">2 (3) </td>
<td align="left">0 (0) </td>
<td align="left">5 (7) </td>
<td align="left">0 (0) </td>
<td align="left">1 (1) </td>
</tr>
<tr><td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td></tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </td>
<td align="left">5 (7) </td>
<td align="left">1 (1) </td>
<td align="left">1 (1) </td>
<td align="left">2 (3) </td>
<td align="left">4 (5) </td>
<td align="left">2 (3) </td>
</tr>
<tr><td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span></td></tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span> </td>
<td align="left">1 (1) </td>
<td align="left">4 (5) </td>
<td align="left">2 (3) </td>
<td align="left">3 (4) </td>
<td align="left">1 (1) </td>
<td align="left">1 (1) </td>
</tr>
<tr><td align="left"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span></td></tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span> </td>
<td align="left">1 (1) </td>
<td align="left">2 (3) </td>
<td align="left">2 (3) </td>
<td align="left">4 (5) </td>
<td align="left">1 (1) </td>
<td align="left">2 (3) </td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span> </td>
<td align="left">1 (1) </td>
<td align="left">1 (1) </td>
<td align="left">4 (5) </td>
<td align="left">1 (1) </td>
<td align="left">0 (0) </td>
<td align="left">3 (4) </td>
</tr>
<tr><td align="left"><span class="Bold">Nervous system</span></td></tr>
<tr class="Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </td>
<td align="left">4 (5) </td>
<td align="left">7 (9) </td>
<td align="left">5 (7) </td>
<td align="left">9 (12) </td>
<td align="left">7 (9) </td>
<td align="left">8 (11) </td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">Application site reactions</span> were reported in 3 out of 226 (1.3%) women treated 
with Evamist.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2>6.2 Additional Adverse Reactions Reported With Estrogen and/or Progestin Therapy</h2>
<p class="First">The following additional adverse reactions have been reported 
with estrogen and/or progestin therapy.</p>
<a href="http://"></a><a href="http://"></a><p><span class="Italics">Genitourinary System</span></p>
<p>Abnormal <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span>/spotting, <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>/<span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">pelvic pain</span>, increase in 
size of uterine leiomyomata, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> including <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span>, change in 
amount of cervical secretion, changes in cervical <span class="product-label-link" type="condition" conceptid="376132" conceptname="Ectropion">ectropion</span>, ovarian cancer, 
<span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>, endometrial cancer.</p>
<a href="http://"></a><a href="http://"></a><p><span class="Italics">Breasts</span></p>
<p><span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">Tenderness</span>, enlargement, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4181744" conceptname="Discharge from nipple">nipple discharge</span>, <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>, fibrocystic 
breast changes, breast cancer.</p>
<a href="http://"></a><a href="http://"></a><p><span class="Italics">Cardiovascular</span></p>
<p>Deep and superficial <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, 
<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, increase in blood pressure.</p>
<a href="http://"></a><a href="http://"></a><p><span class="Italics">Gastrointestinal</span></p>
<p><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, increased 
incidence of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, enlargement of hepatic 
<span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span>.</p>
<a href="http://"></a><a href="http://"></a><p><span class="Italics">Skin</span></p>
<p><span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">Chloasma</span> or <span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">melasma</span>, that may persist when drug is discontinued; <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> 
multiforme, <span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span>, hemorrhagic <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruption</span>, loss of scalp hair, 
<span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
<a href="http://"></a><a href="http://"></a><p><span class="Italics">Eyes</span></p>
<p>Retinal vascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, intolerance to contact lenses.</p>
<a href="http://"></a><a href="http://"></a><p><span class="Italics">Central Nervous System</span></p>
<p><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, exacerbation of <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span>, 
<span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, mood disturbances, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, exacerbation of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, 
<span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>.</p>
<a href="http://"></a><a href="http://"></a><p><span class="Italics">Miscellaneous</span></p>
<p>Increase or decrease in weight, <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">glucose intolerance</span>, aggravation of 
<span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgias</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, changes in libido, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, 
<span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, anaphylactoid/<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> (preexisting 
condition), <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>, increased triglycerides.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">No formal drug interaction studies have been conducted for Evamist.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2>7.1 Metabolic Interactions</h2>
<p class="First">In vitro and in vivo studies have shown that estrogens are metabolized partially 
by cytochrome P450 3A4 (CYP3A4). Therefore, inducers or inhibitors of CYP3A4 may 
affect estrogen drug metabolism. Inducers of CYP3A4 such as St. John's Wort 
preparations (Hypericum perforatum), phenobarbital, carbamazepine, and rifampin 
may reduce plasma concentrations of estrogens, possibly resulting in a decrease 
in therapeutic effects and/or changes in the <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> profile. 
Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, 
itraconazole, ritonavir and grapefruit juice may increase plasma concentrations 
of estrogens and may result in side effects.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Evamist should not be used during pregnancy <span class="Italics">[see 
Contraindications (<a href="#s7">4</a>)]</span>. There appears to be little or 
no increased risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in children born to women who have used 
estrogens and progestins as an oral contraceptive inadvertently during early 
pregnancy.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Evamist should not be used during lactation. Estrogen administration to nursing 
mothers has been shown to decrease the quantity and quality of the milk. 
Detectable amounts of estrogens have been identified in the milk of mothers 
receiving this drug.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Evamist is not intended for pediatric use and no clinical data have been 
collected in children.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">There have not been sufficient numbers of geriatric women 
involved in studies utilizing Evamist to determine whether those over 65 years 
of age differ from younger subjects in their response to Evamist.</p>
<p>In the estrogen alone substudy of the Women's Health Initiative (WHI) study, 
46 percent (n = 4,943) of women were 65 years of age and older, while 7.1 
percent (n = 767) of women were 75 years of age and older. There was a higher 
relative risk (daily conjugated estrogens [CE 0.625 mg] versus placebo) of 
<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in women less than 75 years of age compared to women 75 years of age and 
older.</p>
<p>In the estrogen alone substudy of the Women's Health Initiative Memory Study 
(WHIMS), a substudy of WHI, a population of 2,947 hysterectomized women, 65 to 
79 years of age, was randomized to receive daily conjugated estrogens (CE 0.625 
mg) or placebo. After an average follow-up of 5.2 years, the relative risk (CE 
versus placebo) of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> was 1.49 (95 percent CI, 0.83-2.66). The 
absolute risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> with estrogen alone was 37 versus 
25 cases per 10,000 women-years compared to placebo.</p>
<p>Of the total number of women in the estrogen plus progestin substudy of WHI, 
44 percent (n = 7,320) were 65 years of age and older, while 6.6 percent 
(n = 1,095) were 75 years of age and older. In women 75 years of age and older 
compared to women less than 75 years of age, there was a higher relative risk of 
non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and invasive breast cancer in the estrogen plus progestin group 
versus placebo. In women greater than 75 years of age, the increased risk of 
non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and invasive breast cancer observed in the estrogen plus 
progestin group compared to placebo was 75 versus 24 per 10,000 women-years and 
52 versus 12 per 10,000 women-years, respectively.</p>
<p>In the estrogen plus progestin WHIMS substudy, a population of 4,532 
postmenopausal women, 65 to 79 years of age, was randomized to receive daily CE 
0.625 mg/MPA 2.5 mg or placebo. In the estrogen plus progestin group, after an 
average follow-up of 4 years, the relative risk (CE/MPA versus placebo) of 
probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> was 2.05 (95 percent CI, 1.21-3.48). The absolute risk of 
developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> with CE/MPA was 45 versus 22 cases per 10,000 
women-years compared to placebo.</p>
<p>Seventy-nine (79) percent of the cases of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> occurred in women 
that were older than 70 for the CE alone group, and 82 percent of the cases of 
probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> occurred in women who were older than 70 in the CE/MPA group. 
The most common classification of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in both the treatment groups 
and placebo groups was Alzheimer's disease.</p>
<p>When data from the two populations were pooled as planned in the WHIMS 
protocol, the reported overall relative risk for probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> was 1.76 (95 
percent CI, 1.19-2.60). Since both substudies were conducted in women 65 to 79 
years of age, it is unknown whether these findings apply to younger 
postmenopausal women <span class="Italics">[see Warnings and Precautions (<a href="#s17">5.3</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Overdosage of estrogen may cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span>, 
<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> may occur 
in women. Treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> consists of discontinuation of Evamist together 
with institution of appropriate symptomatic care.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Evamist (estradiol transdermal spray) is designed to deliver 
estradiol to the blood circulation following topical application to the skin of 
a rapidly drying solution from a metered-dose pump.</p>
<p>Evamist is a homogeneous solution of 1.7% estradiol USP (active ingredient) 
in alcohol USP and octisalate USP formulated to provide sustained release of the 
active ingredient into the systemic circulation.</p>
<p>Estradiol USP is a white crystalline powder, chemically described as 
estra-1,3,5(<a href="#s52">10</a>)-triene-3,17β-diol. It has an empirical 
formula of C<span class="Sub">18</span>H<span class="Sub">24</span>O<span class="Sub">2</span>·1/2 H<span class="Sub">2</span>O and molecular weight of 281.4. 
The structural formula is:</p>
<p><img alt="image of chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d8c4a929-c039-4c7d-a3bc-986ae31fc8a6&amp;name=evamist-01.jpg"></p>
<p>Each metered-dose pump contains 8.1 mL and is designed to accurately deliver 
75 sprays of 90 mcL each after priming. One spray of Evamist contains 1.53 mg 
estradiol. The metered-dose pump should be held upright and vertical for 
spraying. Before a new applicator is used for the first time, the pump should be 
primed by spraying 3 times into the cover. </p>
<p>One, two or three sprays are applied daily to adjacent non-overlapping 20 
cm<span class="Sup">2</span> areas on the inner surface of the arm between the 
elbow and the wrist and allowed to dry.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Endogenous estrogens are largely responsible for the development 
and maintenance of the female reproductive system and secondary sexual 
characteristics. Although circulating estrogens exist in a dynamic equilibrium 
of metabolic interconversions, estradiol is the principal intracellular human 
estrogen and is substantially more potent than its metabolites, estrone and 
estriol, at the receptor level.</p>
<p>The primary source of estrogen in normally cycling adult women is the ovarian 
follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the 
phase of the menstrual cycle. After <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, most endogenous estrogen is 
produced by conversion of androstenedione, secreted by the adrenal cortex, to 
estrone by peripheral tissues. Thus, estrone and the sulfate conjugated form, 
estrone sulfate, are the most abundant circulating estrogens in postmenopausal 
women.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Estrogens act through binding to nuclear receptors in 
estrogen-responsive tissues. To date, two estrogen receptors have been 
identified. These vary in proportions from tissue to tissue.</p>
<p>Circulating estrogens modulate the pituitary secretion of the gonadotropins, 
luteinizing hormone (LH) and follicle stimulating hormone (FSH), through a 
negative feedback mechanism. Estrogens act to reduce the elevated levels of 
these hormones seen in postmenopausal women.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Italics">Absorption</span></p>
<p>In a multiple-dose study, 72 postmenopausal women were treated for 14 days 
with Evamist to the inner forearm. Serum concentrations of estradiol appeared to 
reach steady state after 7 to 8 days of application of one, two, or three 90-mcL 
sprays of Evamist per day (<a href="#f02">Figure 1</a>).</p>
<p><img alt="image of figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d8c4a929-c039-4c7d-a3bc-986ae31fc8a6&amp;name=evamist-02.jpg"></p>
<p></p>
<p>Figure 1. Mean (±SD) Serum Estradiol Concentrations 
on Day 14 Following Topical Application for 14 Days of One, Two or Three Sprays 
of Evamist (Unadjusted for Baseline)</p>
<p>Pharmacokinetics parameters for estradiol from one, two, or three 90-mcL 
sprays of Evamist, as assessed on Day 14 of this study, are described in <a href="#t2">Table 2</a>.</p>
<a href="http://"></a><a name="i825c5323-0a28-4d9f-805a-db7a7c4307a3"></a><table width="100%">
<caption><span>Table 2. Estradiol Pharmacokinetic Parameters on Day 14 (Unadjusted for 
Baseline)</span></caption>
<col align="left" width="38%">
<col align="left" width="18%">
<col align="left" width="22%">
<col align="left" width="20%">
<thead>
<tr class="First">
<th align="left">PK 
Parameter </th>
<th align="left" colspan="3"><span class="Bold">Number of Daily Sprays of Evamist</span></th>
</tr>
<tr class="Last">
<th align="left"><span class="Bold">1 Spray 
<br>(N = 24)</span></th>
<th align="left"><span class="Bold">2 Spray 
<br>(N = 23)</span></th>
<th align="left"><span class="Bold">3 Spray 
<br>(N = 24)</span></th>
</tr>
</thead>
<tbody><tr class="First Last">
<td align="left">C<span class="Sub">max</span> 
(pg/mL)<span class="Sup">1</span><br>C<span class="Sub">min</span> (pg/mL)<span class="Sup">1</span><br>C<span class="Sub">avg</span> (pg/mL)<span class="Sup">1</span><br><span class="Sub"></span>AUC<span class="Sub">0-24</span> 
(pg*hr/mL)<span class="Sup">1</span><br>T<span class="Sub">max</span> (hours)<span class="Sup">2</span>
</td>
<td align="left">36.4 (62) <br>11.3 (52) 
<br>19.6 (49) <br>471 (49) <br>20 (0-24) </td>
<td align="left">57.4 (94) <br>18.1 (51) 
<br>30.7 (43) <br>736 (43) <br>18 (0-24) </td>
<td align="left">54.1 (50) <br>19.6 (27) 
<br>30.9 (30) <br>742 (30) <br>20 (0-24) </td>
</tr></tbody>
</table>
<a href="http://"></a><a href="http://"></a><p><span class="Sup">1</span> Values expressed are arithmetic 
means (%CV)<br><span class="Sup">2</span> Values expressed are medians 
(minimum-maximum)</p>
<p><span class="Italics"><br></span></p>
<p><span class="Italics">Distribution</span></p>
<p>The distribution of exogenous estrogens is similar to that of endogenous 
estrogens. Estrogens are widely distributed in the body and are generally found 
in higher concentrations in the sex hormone target organs. Estrogens circulate 
in blood largely bound to <span class="product-label-link" type="condition" conceptid="4206320" conceptname="Sex steroid binding globulin">sex hormone binding globulin</span> (SHBG) and albumin.</p>
<a href="http://"></a><a href="http://"></a><p><span class="Italics">Metabolism</span></p>
<p>Exogenous estrogens are metabolized in the same manner as endogenous 
estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic 
interconversions. These transformations take place mainly in the liver. 
Estradiol is converted reversibly to estrone, and both can be converted to 
estriol, which is a major urinary metabolite. Estrogens also undergo 
enterohepatic recirculation via sulfate and glucuronide conjugation in the 
liver, biliary secretion of conjugates into the intestine, and hydrolysis in the 
intestine followed by reabsorption. In postmenopausal women, a significant 
proportion of the circulating estrogens exist as sulfate conjugates, especially 
estrone sulfate, which serves as a circulating reservoir for the formation of 
more active estrogens.</p>
<a href="http://"></a><a href="http://"></a><p><span class="Italics">Excretion</span></p>
<p>Estradiol, estrone and estriol are excreted in the urine along with 
glucuronide and sulfate conjugates.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term continuous administration of natural and synthetic estrogens in 
certain animal species increases the frequency of carcinomas of the breast, 
uterus, cervix, vagina, testis and liver.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<h2>14.1 Effects on Vasomotor Symptoms</h2>
<p class="First">In a 12-week, randomized, double-blind, placebo-controlled 
clinical trial, a total of 454 postmenopausal women (average 53 years of age, 70 
percent Caucasian and 24 percent African-American) were randomized and received 
at least one dose of Evamist (one, two or three 90-mcL sprays) or placebo. 
Generally healthy postmenopausal women were enrolled with a mean total frequency 
of greater than or equal to 56 moderate to severe vasomotor symptoms per week (greater than or equal to 8 per day).</p>
<p>Efficacy was determined as a statistically significant and clinically 
significant (at least two per day or 14 per week difference) reduction in hot 
flush frequency and a statistically significant reduction in severity for 
Evamist versus placebo. One, two or three daily sprays of Evamist were shown to 
be better than placebo for relief of frequency (<a href="#section-">  Table 3</a>) and 
severity (<a href="#section-">  Table 4</a>) of moderate to severe vasomotor symptoms at 
Week 4 and Week 12.</p>
<a href="#section-"></a><a name="i3bdb3505-e490-463b-839f-bc98e4a46eb4"></a><table width="100%">
<caption><span>Table 3. Effect of Treatment on the Daily Frequency of Moderate to 
Severe Vasomotor Symptoms at Week 4 and Week 12 (Intent-To-Treat Population, 
LOCF)</span></caption>
<col align="left" width="21%">
<col align="left" width="21%">
<col align="left" width="28%">
<col align="left" width="28%">
<thead>
<tr class="First">
<th align="left" colspan="2"><br></th>
<th align="left" colspan="2">
<span class="Bold">Mean Change from Baseline</span><span class="Sup">a</span><span class="Bold">(SD)</span>
</th>
</tr>
<tr class="Last">
<th align="left">
<span class="Bold">Treatment</span><br><span class="Bold">(N)</span>
</th>
<th align="left"><span class="Bold">Baseline 
<br>Mean (SD)</span></th>
<th align="left"><span class="Bold">Week 4 
<br>Mean (SD)</span></th>
<th align="left"><span class="Bold">Week 12 
<br>Mean (SD)</span></th>
</tr>
</thead>
<tbody>
<tr class="First"><td align="left"><span class="Bold">1 Spray</span></td></tr>
<tr>
<td align="left">Evamist (N=76) </td>
<td align="left">11.81 (4.07) </td>
<td align="left">-6.26 (4.01) </td>
<td align="left">-8.10 (4.02) </td>
</tr>
<tr>
<td align="left">Placebo (N=77) </td>
<td align="left">12.41 (5.59) </td>
<td align="left">-3.64 (5.30) </td>
<td align="left">-4.76 (5.84) </td>
</tr>
<tr>
<td align="left">Difference<span class="Sup">b</span>
</td>
<td align="left">— </td>
<td align="left">-2.62 </td>
<td align="left">-3.34 </td>
</tr>
<tr>
<td align="left">p-value<span class="Sup">c</span>
</td>
<td align="left">— </td>
<td align="left">0.0010 </td>
<td align="left">0.0004 </td>
</tr>
<tr><td align="left"><span class="Bold">2 Sprays</span></td></tr>
<tr>
<td align="left">Evamist (N=74) </td>
<td align="left">12.66 (7.33) </td>
<td align="left">-7.30 (6.93) </td>
<td align="left">-8.66 (6.65) </td>
</tr>
<tr>
<td align="left">Placebo (N=76) </td>
<td align="left">12.13 (6.10) </td>
<td align="left">-4.74 (4.38) </td>
<td align="left">-6.19 (5.77) </td>
</tr>
<tr>
<td align="left">Difference<span class="Sup">b</span>
</td>
<td align="left">— </td>
<td align="left">-2.56 </td>
<td align="left">-2.47 </td>
</tr>
<tr>
<td align="left">p-value<span class="Sup">c</span>
</td>
<td align="left">— </td>
<td align="left">0.0027 </td>
<td align="left">0.0099 </td>
</tr>
<tr><td align="left"><span class="Bold">3 Sprays</span></td></tr>
<tr>
<td align="left">Evamist (N=76) </td>
<td align="left">10.78 (3.58) </td>
<td align="left">-6.64 (4.23) </td>
<td align="left">-8.44 (4.50) </td>
</tr>
<tr>
<td align="left">Placebo (N=75) </td>
<td align="left">12.55 (11.94) </td>
<td align="left">-4.54 (7.40) <br>
</td>
<td align="left">-5.32 (6.30) </td>
</tr>
<tr>
<td align="left">Difference<span class="Sup">b</span>
</td>
<td align="left">— </td>
<td align="left">-2.10 </td>
<td align="left">-3.12 </td>
</tr>
<tr class="Last">
<td align="left">p-value<span class="Sup">c</span>
</td>
<td align="left">— </td>
<td align="left">0.0002 </td>
<td align="left">less than 0.0001 </td>
</tr>
</tbody>
</table>
<span class="Sup">a</span> Mean change and difference based on raw data<br><span class="Sup">b</span> Evamist versus placebo<br><span class="Sup">c</span> Tests for pairwise differences using ANCOVA<br><br><br><a name="ie35160f8-dd2a-4cc1-84f0-8c8fc5ac9c71"></a><table width="100%">
<caption><span>Table 4. Effect of Treatment on the Weekly Severity of Moderate to 
Severe Vasomotor Symptoms at Week 4 and Week 12 (Intent-To-Treat Population, 
LOCF) <span class="Sup">a</span></span></caption>
<col align="left" width="21%">
<col align="left" width="21%">
<col align="left" width="28%">
<col align="left" width="28%">
<thead>
<tr class="First">
<th align="left" colspan="2"><br></th>
<th align="left" colspan="2">
<span class="Bold">Mean Change from Baseline</span><span class="Sup">b</span><span class="Bold">(SD)</span>
</th>
</tr>
<tr class="Last">
<th align="left">
<span class="Bold">Treatment</span><br><span class="Bold">(N)</span>
</th>
<th align="left"><span class="Bold">Baseline 
<br>Mean (SD)</span></th>
<th align="left"><span class="Bold">Week 4 
<br>Mean (SD)</span></th>
<th align="left"><span class="Bold">Week 12 
<br>Mean (SD)</span></th>
</tr>
</thead>
<tbody>
<tr class="First"><td align="left"><span class="Bold">1 Spray</span></td></tr>
<tr>
<td align="left">Evamist (N=76) </td>
<td align="left">2.53 (0.25) </td>
<td align="left">-0.47 (0.80) </td>
<td align="left">-1.04 (1.01) </td>
</tr>
<tr>
<td align="left">Placebo (N=77) </td>
<td align="left">2.55 (0.25) </td>
<td align="left">-0.19 (0.55) </td>
<td align="left">-0.26 (0.60) </td>
</tr>
<tr>
<td align="left">Difference<span class="Sup">c</span>
</td>
<td align="left">— </td>
<td align="left">-0.28 </td>
<td align="left">-0.78 </td>
</tr>
<tr>
<td align="left">p-value<span class="Sup">d</span>
</td>
<td align="left">— </td>
<td align="left">0.0573 </td>
<td align="left">less than 0.0001 </td>
</tr>
<tr><td align="left"><span class="Bold">2 Sprays</span></td></tr>
<tr>
<td align="left">Evamist (N=74) </td>
<td align="left">2.54 (0.21) </td>
<td align="left">-0.57 (0.83) </td>
<td align="left">-0.92 (1.01) </td>
</tr>
<tr>
<td align="left">Placebo (N=76) </td>
<td align="left">2.54 (0.22) </td>
<td align="left">-0.25 (0.64) </td>
<td align="left">-0.54 (0.89) </td>
</tr>
<tr>
<td align="left">Difference<span class="Sup">c</span>
</td>
<td align="left">— </td>
<td align="left">-0.32 </td>
<td align="left">-0.38 </td>
</tr>
<tr>
<td align="left">p-value<span class="Sup">d</span>
</td>
<td align="left">— </td>
<td align="left">0.0160 </td>
<td align="left">0.0406 </td>
</tr>
<tr><td align="left"><span class="Bold">3 Sprays</span></td></tr>
<tr>
<td align="left">Evamist (N=76) </td>
<td align="left">2.58 (0.25) </td>
<td align="left">-0.43 (0.66) </td>
<td align="left">-1.07 (1.01) </td>
</tr>
<tr>
<td align="left">Placebo (N=75) </td>
<td align="left">2.54 (0.24) </td>
<td align="left">-0.13 (0.53) </td>
<td align="left">-0.31 (0.75) </td>
</tr>
<tr>
<td align="left">Difference<span class="Sup">c</span>
</td>
<td align="left">— </td>
<td align="left">-0.30 </td>
<td align="left">-0.76 </td>
</tr>
<tr class="Last">
<td align="left">p-value<span class="Sup">d</span>
</td>
<td align="left">— </td>
<td align="left">0.0031 </td>
<td align="left">less than 0.0001 </td>
</tr>
</tbody>
</table>
<span class="Sup">a</span> Severity score calculated as: (2 x number moderate +3 x number severe)/ number moderate + number severe)<br><span class="Sup">b</span> Mean chane and difference based on raw data<br><span class="Sup">c</span> Evamist versus placebo<br><span class="Sup">d</span> Tests for pairwise differences using ANCOVA<br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2"></a><p></p>
<h2>14.2 Effect of Application Site Washing</h2>
<p class="First">Site washing one hour after the application of three 90-mcL sprays to the inner 
forearm did not have a significant effect on average 24-hour serum 
concentrations of estradiol.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.3"></a><p></p>
<h2>14.3 Potential for Estradiol Transfer</h2>
<p class="First">The effect of estradiol transfer was evaluated in 20 healthy postmenopausal 
women who applied three 90-mcL sprays of Evamist to the inner forearm once 
daily. One hour after applying Evamist, subjects held the dosed forearm against 
the inner forearm of a non-dosed (recipient) male subject for one 5-minute 
period of continual contact. No significant transfer of estradiol was observed 
in persons who came in contact with the application site of estradiol-treated 
individuals.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.4"></a><p></p>
<h2>14.4 Women's Health Initiative Studies</h2>
<p class="First">The Women's Health Initiative (WHI) enrolled approximately 27,000 
predominantly healthy postmenopausal women in two substudies to assess the risks 
and benefits of either the use of daily oral conjugated estrogens (CE 0.625 mg) 
alone or in combination with medroxyprogesterone acetate (MPA 2.5 mg) compared 
to placebo in the prevention of certain chronic diseases. The primary endpoint 
was the incidence of coronary heart disease (CHD) (nonfatal myocardial 
<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> [MI], silent MI and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>), with invasive breast cancer as the 
primary adverse outcome studied. A “global index? included the earliest 
occurrence of CHD, invasive breast cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), 
endometrial cancer (only in the CE/MPA substudy), colorectal cancer, hip 
<span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other cause. These substudies did not evaluate the 
effects of CE or CE/MPA on <span class="product-label-link" type="condition" conceptid="439082" conceptname="Menopausal syndrome">menopausal symptoms</span>.</p>
<p>The estrogen alone substudy was stopped early because an increased risk of 
<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was observed, and it was deemed that no further information would be 
obtained regarding the risks and benefits of estrogen alone in predetermined 
primary endpoints. Results of the estrogen alone substudy, which included 10,739 
women (average 63 years of age, range 50 to 79 years of age; 75.3 percent White, 
15.1 percent Black, 6.1 percent Hispanic, 3.6 percent Other), after an average 
follow-up of 6.8 years are presented in <a href="#t5">Table 5</a>.</p>
<p>For those outcomes included in the WHI “global index? that reached 
statistical significance, the absolute excess risk per 10,000 women-years in the 
group treated with CE alone was 12 more <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, while the absolute risk 
reduction per 10,000 women-years was 6 fewer <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fractures</span>. The absolute excess 
risk of events included in the “global index? was a non-significant 2 events per 
10,000 women-years. There was no difference between the groups in terms of 
all-cause mortality <span class="Italics">[see Warnings and Precautions (<a href="#s8">5</a>)]</span>.</p>
<p>Final centrally adjudicated results for CHD events and centrally adjudicated 
results for invasive breast cancer incidence from the estrogen alone substudy, 
after an average follow-up of 7.1 years, reported no overall difference for 
primary CHD events (nonfatal MI, silent MI and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) and invasive breast 
cancer incidence in women receiving CE alone compared to placebo (see <a href="#t5">Table 5</a>).<span class="Sup">2,4</span></p>
<p>Centrally adjudicated results for <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> events from the estrogen alone 
substudy, after an average follow-up of 7.1 years, reported no significant 
differences in distribution of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> subtypes or severity, including fatal 
<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, in women receiving CE alone compared to placebo. Estrogen alone 
increased the risk for <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic stroke</span>, and this excess risk was present in all 
subgroups of women examined (see <a href="#t5">Table 5</a>).<span class="Sup">1</span></p>
<p>The estrogen plus progestin substudy was also stopped early. According to the 
predefined stopping rule, after an average follow-up of 5.2 years of treatment, 
the increased risk of breast cancer and cardiovascular events exceeded the 
specified benefits included in the “global index.? The absolute excess risk of 
events included in the “global index? was 19 per 10,000 women-years (relative 
risk [RR] 1.15, 95 percent nCI, 1.03-1.28).</p>
<p>For those outcomes included in the WHI “global index? that reached 
statistical significance after 5.6 years of follow-up, the absolute excess risks 
per 10,000 women-years in the group treated with CE/MPA were 6 more CHD events, 
7 more <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, 10 more PEs, and 8 more invasive breast cancers, while the 
absolute risk reduction per 10,000 women-years were 7 fewer colorectal cancers 
and 5 fewer <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fractures</span> <span class="Italics">[see Warnings and Precautions (<a href="#s8">5</a>)]</span>.</p>
<p>Results of the estrogen plus progestin substudy, which included 16,608 women 
(average 63 years of age, range 50 to 79 years of age; 83.9 percent White, 6.5 
percent Black, 5.4 percent Hispanic, 3.9 percent Other) are presented in <a href="#t6">Table 6</a>. These results reflect centrally adjudicated data after 
an average follow-up of 5.6 years.</p>
<a href="http://"></a><a name="if68eb2dd-eb96-47e9-87bf-77d116c14cab"></a><table width="100%">
<caption><span>Table 5. Relative and Absolute Risk Seen in the Estrogen Alone Substudy 
of WHI </span></caption>
<col align="left" width="35%">
<col align="left" width="26%">
<col align="left" width="19%">
<col align="left" width="19%">
<thead>
<tr class="First">
<th align="left"><span class="Bold">Event</span></th>
<th align="left"><span class="Bold">Relative Risk <br>CE vs. Placebo <br>(95% nCI<span class="Sup">a</span>)</span></th>
<th align="left">
<span class="Bold">Placebo</span><br><span class="Bold">(n = 5,429)</span>
</th>
<th align="left"><span class="Bold">CE 
<br>(n = 5,310)</span></th>
</tr>
<tr class="Last"><th align="left" colspan="2"><span class="Bold">Absolute Risk per 10,000 Women-Years</span></th></tr>
</thead>
<tbody>
<tr class="First">
<td align="left">CHD events<span class="Sup">b</span><br><span class="Italics">   Non-fatal MI</span><span class="Sup">b</span><br><span class="Italics">   CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></span><span class="Sup">b</span>
</td>
<td align="left">0.95 (0.79-1.16) <br><span class="Italics">0.91 (0.73-1.14)</span><br><span class="Italics">1.01 
(0.71-1.43)</span>
</td>
<td align="left">56 <br><span class="Italics">43</span><br><span class="Italics">16</span>
</td>
<td align="left">53 <br><span class="Italics">40</span><br><span class="Italics">16</span>
</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span><span class="Sup">b</span><br><span class="Italics">   Ischemic</span><span class="Sup">b</span>
</td>
<td align="left">1.37 (1.09-1.73) <br><span class="Italics">1.55 (1.19-2.01)</span>
</td>
<td align="left">33 <br><span class="Italics">25</span>
</td>
<td align="left">45 <br><span class="Italics">38</span>
</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep vein thrombosis</span><span class="Sup">b,d</span>
</td>
<td align="left">1.47 (1.06-2.06) </td>
<td align="left">15 </td>
<td align="left">23 </td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span><span class="Sup">b</span>
</td>
<td align="left">1.37 (0.90-2.07) </td>
<td align="left">10 </td>
<td align="left">14 </td>
</tr>
<tr>
<td align="left">Invasive breast cancer<span class="Sup">b</span>
</td>
<td align="left">0.80 (0.62-1.04) </td>
<td align="left">34 </td>
<td align="left">28 </td>
</tr>
<tr>
<td align="left">Colorectal cancer<span class="Sup">c</span>
</td>
<td align="left">1.08 (0.75-1.55) </td>
<td align="left">16 </td>
<td align="left">17 </td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">Hip fracture</span><span class="Sup">c</span>
</td>
<td align="left">0.61 (0.41-0.91) </td>
<td align="left">17 </td>
<td align="left">11 </td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">Vertebral fractures</span><span class="Sup">c,d</span>
</td>
<td align="left">0.62 (0.42-0.93) </td>
<td align="left">17 </td>
<td align="left">11 </td>
</tr>
<tr>
<td align="left">Total <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span><span class="Sup">c,d</span>
</td>
<td align="left">0.70 (0.63-0.79) </td>
<td align="left">195 </td>
<td align="left">139 </td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> due to other causes 
</td>
<td align="left">1.08 (0.88-1.32) </td>
<td align="left">50 </td>
<td align="left">53 </td>
</tr>
<tr>
<td align="left">Overall mortality<span class="Sup">c,d</span>
</td>
<td align="left">1.04 (0.88-1.22) </td>
<td align="left">78 </td>
<td align="left">81 </td>
</tr>
<tr class="Last">
<td align="left">Global index<span class="Sup">c,f</span>
</td>
<td align="left">1.01 (0.91-1.12) </td>
<td align="left">190 </td>
<td align="left">192 
</td>
</tr>
</tbody>
</table>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><br><p><span class="Sup">a</span> Nominal confidence intervals 
unadjusted for multiple looks and multiple comparisons.<br><span class="Sup">b</span> Results are based on centrally 
adjudicated data for an average follow-up of 7.1 years.<br><span class="Sup">c</span> Results are based on an average 
follow-up of 6.8 years.<br><span class="Sup">d</span> Not included in global 
index.<br><span class="Sup">e</span> All <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, except from breast 
or colorectal cancer, definite/probable CHD, PE or cerebrovascular disease.<br><span class="Sup">f</span> A subset of the events was 
combined in a “global index,? defined as the earliest occurrence of CHD events, 
invasive breast cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, endometrial cancer, 
colorectal cancer, <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fracture</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other causes.</p>
<br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.5"></a><p></p>
<h2>14.5 Women's Health Initiative Memory Study</h2>
<p class="First">The estrogen alone Women's Health Initiative Memory Study 
(WHIMS), a substudy of theWHI, enrolled 2,947 predominantly healthy 
postmenopausal women 65 years of age and older (45 percent were 65 to 69 years 
of age, 36 percent were 70 to 74 years of age, and 19 percent were 75 years of 
age and older) to evaluate the effects of daily conjugated estrogen (CE 0.625 
mg) on the incidence of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (primary outcome) compared to 
placebo.</p>
<p>After an average follow-up of 5.2 years, 28 women in the estrogen alone group 
(37 per 10,000 women-years) and 19 in the placebo group (25 per 10,000 
women-years) were diagnosed with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk of 
probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in the estrogen alone group was 1.49 (95 percent CI, 
0.83-2.66) compared to placebo. It is unknown whether these findings apply to 
younger postmenopausal women <span class="Italics">[see Warnings and Precautions 
(<a href="#s17">5.3</a>) and Use in Specific Populations (<a href="#s51">8.5</a>)]</span>.</p>
<p>The estrogen plus progestin WHIMS substudy enrolled 4,532 predominantly 
healthy postmenopausal women 65 years of age and older (47 percent were 65 to 69 
years of age, 35 percent were 70 to 74 years of age, and 18 percent were 75 
years of age and older) to evaluate the effects of daily CE 0.625 mg plus 
medroxyprogesterone acetate (MPA 2.5 mg) on the incidence of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> 
(primary outcome) compared to placebo.</p>
<p>After an average follow-up of 4 years, 40 women in the estrogen plus 
progestin group (45 per 10,000 women-years) and 21 in the placebo group (22 per 
10,000 women-years) were diagnosed with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk of 
probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in the hormone therapy group was 2.05 (95 percent CI, 1.21- 
3.48) compared to placebo.</p>
<p>When data from the two populations were pooled as planned in the WHIMS 
protocol, the reported overall relative risk for probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> was 1.76 (95 
percent CI, 1.19-2.60). Differences between groups became apparent in the first 
year of treatment. It is unknown whether these findings apply to younger 
postmenopausal women <span class="Italics">[see Warnings and Precautions (<a href="#s17">5.3</a>) and Use in Specific Populations (<a href="#s51">8.5</a>)]</span>.</p>
<a href="http://"></a><a name="id2fbb8c1-3c50-4c65-888c-5ae0e155f7f4"></a><table width="100%">
<caption><span>Table 6. Relative and Absolute Risk Seen in the Estrogen Plus Progestin 
Substudy of WHI at an Average of 5.6 Years<span class="Sup">a</span></span></caption>
<col align="left" width="34%">
<col align="left" width="28%">
<col align="left" width="18%">
<col align="left" width="18%">
<thead>
<tr class="First">
<th align="left"><span class="Bold">Event</span></th>
<th align="left">
<span class="Bold">Relative Risk CE/MPA vs. Placebo</span><span class="Bold"><br></span><span class="Bold">(95% nCI</span><span class="Sup">b</span><span class="Bold">)</span>
</th>
<th align="left">
<span class="Bold">Placebo</span><br><span class="Bold">(n = 8,102)</span>
</th>
<th align="left"><span class="Bold">CE/MPA 
<br>(n = 8,506)</span></th>
</tr>
<tr class="Last"><th align="left" colspan="2"><span class="Bold">Absolute Risk per 10,000 Women-Years</span></th></tr>
</thead>
<tbody>
<tr class="First">
<td align="left">CHD events <br><span class="Italics">   Non-fatal MI</span><br><span class="Italics">   CHD 
<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></span>
</td>
<td align="left">1.24 (1.00-1.54) <br><span class="Italics">1.28 (1.00-1.63)</span><br><span class="Italics">1.10 
(0.70-1.75)</span>
</td>
<td align="left">33 <br><span class="Italics">25</span><br><span class="Italics">8</span>
</td>
<td align="left">39 <br><span class="Italics">31</span><br><span class="Italics">8</span>
</td>
</tr>
<tr>
<td align="left">All <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> <br><span class="Italics">   <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic stroke</span></span>
</td>
<td align="left">1.31 (1.02-1.68) <br><span class="Italics">1.44 (1.09-1.90)</span>
</td>
<td align="left">24 <br><span class="Italics">18</span>
</td>
<td align="left">31 <br><span class="Italics">26</span>
</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep vein thrombosis</span> </td>
<td align="left">1.95 (1.43-2.67) </td>
<td align="left">13 </td>
<td align="left">26 </td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span> </td>
<td align="left">2.13 (1.45-3.11) </td>
<td align="left">8 </td>
<td align="left">18 </td>
</tr>
<tr>
<td align="left">Invasive breast cancer<span class="Sup">c</span>
</td>
<td align="left">1.24 (1.01-1.54) </td>
<td align="left">33 </td>
<td align="left">41 </td>
</tr>
<tr>
<td align="left">Invasive colorectal cancer 
</td>
<td align="left">0.56 (0.38-0.81) </td>
<td align="left">16 </td>
<td align="left">9 </td>
</tr>
<tr>
<td align="left">Endometrial cancer </td>
<td align="left">0.81 (0.48-1.36) </td>
<td align="left">7 </td>
<td align="left">6 </td>
</tr>
<tr>
<td align="left">Cervical cancer </td>
<td align="left">1.44 (0.47-4.42) </td>
<td align="left">1 </td>
<td align="left">2 </td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">Hip fracture</span> </td>
<td align="left">0.67 (0.47-0.96) </td>
<td align="left">16 </td>
<td align="left">11 </td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">Vertebral fractures</span> </td>
<td align="left">0.65 (0.46-0.92) </td>
<td align="left">17 </td>
<td align="left">11 </td>
</tr>
<tr>
<td align="left">Lower arm/wrist <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> 
</td>
<td align="left">0.71 (0.59-0.85) </td>
<td align="left">62 </td>
<td align="left">44 </td>
</tr>
<tr class="Last">
<td align="left">Total <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> </td>
<td align="left">0.76 (0.69-0.83) </td>
<td align="left">199 </td>
<td align="left">152 </td>
</tr>
</tbody>
</table>
<span class="Sup">a</span> Results are based on centrally 
adjudicated data. Mortality data was not part of the adjudicated data; however, 
data at 5.2 years of follow-up showed no difference between the groups in terms 
of all-cause mortality (RR 0.98, 95 percent nCI, 0.82-1.18).<br><p><span class="Sup">b</span> Nominal confidence intervals 
unadjusted for multiple looks and multiple comparisons.<br><span class="Sup">c</span> Includes metastatic and 
non-metastatic breast cancer, with the exception of in situ breast cancer.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<ol>
<li>Hendrix, SL, et al. Effects of conjugated equine estrogen on <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in the 
Women's Health Initiative. <span class="Italics">Circulation</span>. 
2006;113:2425-2434. </li>
<li>Hsia J, et al. Conjugated equine estrogens and coronary heart disease. <span class="Italics">Arch Int Med.</span> 2006;166:357–365. </li>
<li>Curb JD, et al. <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">Venous thrombosis</span> and conjugated equine estrogen in women 
without a uterus. <span class="Italics">Arch Int Med.</span> 2006; 166:772-780. 
</li>
<li>Stefanick ML, et al. Effects of conjugated equine estrogens on breast cancer 
and mammography </li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Evamist (<span class="Bold">NDC 54868-6157-0</span>) is supplied as a homogeneous solution 
of estradiol USP, octisalate USP and alcohol USP. The liquid formulation of 
Evamist is packaged in a glass vial fitted with a metered-dose pump. The unit is 
encased in a plastic housing with a conical bell opening that controls the 
distance, angle, and area of application of the metered-dose spray. Each 
metered-dose pump contains 8.1 mL and is designed to accurately deliver 75 
sprays of 90 mcL after priming. One spray contains 1.53 mg estradiol.</p>
<p><span class="Bold">Keep out of reach of children.</span></p>
<p>Alcohol and alcohol-based liquids are flammable. Avoid fire, flame or smoking 
until the spray has dried</p>
<p>Store at 25°C (77°F) with excursion permitted to 15° to 30°C (59° to 86°F). 
Do not freeze.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Bold">See FDA-Approved Patient Labeling (<a href="#s75">17.3</a>)</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.1"></a><p></p>
<h2>17.1 <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Bleeding</span></h2>
<p class="First">Inform women of the importance of reporting <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> to their healthcare 
provider as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.2"></a><p></p>
<h2>17.2 Common Adverse Reactions with Estrogen</h2>
<p class="First">Inform women of the possible side effects of estrogen therapy such as <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, 
<span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span> and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-17"></a><p></p>
<h1>17.3 FDA-Approved Patient Labeling</h1>
<p class="First"><span class="Bold">Evamist <br>(estradiol transdermal spray)</span></p>
<p><span class="Bold">Instructions for use. <br>Read carefully.</span></p>
<p>Read this PATIENT INFORMATION before you start using Evamist and read the 
patient information each time you refill your Evamist prescription. There may be 
new information. This information does not take the place of talking to your 
healthcare provider about your <span class="product-label-link" type="condition" conceptid="439082" conceptname="Menopausal syndrome">menopausal symptoms</span> and their treatment.</p>
<a name="i9b44db02-ee2b-45b1-8305-6654261026e8"></a><table width="100%">
<col align="left" width="100%">
<tbody class="Headless">
<tr class="First"><td align="left"><span class="Bold">WHAT IS THE MOST 
IMPORTANT INFORMATION I SHOULD KNOW ABOUT EVAMIST (AN ESTROGEN 
HORMONE)?</span></td></tr>
<tr class="Last"><td align="left"><ul>
<li>Estrogens increase the chance of getting cancer of the uterus. <br>Report 
any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> right away while you are using Evamist. Vaginal 
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may be a warning sign of cancer of the uterus (womb). 
Your healthcare provider should check any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> to find out 
the cause. </li>
<li>Do not use estrogens with or without progestins to prevent heart disease, 
<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. <br>Using estrogens, with or without 
progestins, may increase your chance of getting <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, breast 
cancer, and blood clots. Using estrogen, with or without progestins, may 
increase your chance of getting <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, based on a study of women 65 years of 
age or older. You and your healthcare provider should talk regularly about 
whether you still need treatment with Evamist. 
</li>
</ul></td></tr>
</tbody>
</table>
<p><span class="Bold">What is Evamist?</span></p>
<p>Evamist is a medicine that contains estradiol (an estrogen hormone). When 
applied to the skin, estradiol is absorbed through the skin into the 
bloodstream.</p>
<p><span class="Bold">What is Evamist used for?</span></p>
<p>Evamist is used after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> to:</p>
<ul><li>Reduce moderate to severe <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span> </li></ul>
<p>Estrogens are hormones made by a woman's ovaries. The ovaries normally stop 
making estrogens when a woman is between 45 and 55 years old. This drop in body 
estrogen levels causes the “change of life? or <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> (the end of monthly 
menstrual periods). Sometimes, a woman's ovaries are removed during an operation 
that causes “surgical <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>.?</p>
<p>When the estrogen levels begin dropping, some women get very uncomfortable 
symptoms, such as feelings of warmth in the face, neck, and chest, or sudden 
strong feelings of heat and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> (“hot flashes? or “hot flushes?). In some 
women, the symptoms are mild, and they will not need estrogen treatment. In 
other women, symptoms can be more severe. You and your healthcare provider 
should talk regularly about whether you still need treatment with Evamist.</p>
<p><span class="Bold">Who should not use Evamist?</span></p>
<p>Do not start using Evamist if you:</p>
<ul>
<li><span class="Bold">Have unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span></span></li>
<li><span class="Bold">Currently have or have had certain cancers</span></li>
</ul>
<p>Estrogens may increase the chance of getting certain types of cancers, 
including cancer of the breast or uterus. If you have or have had cancer, talk 
with your healthcare provider about whether you should use Evamist.</p>
<ul>
<li><span class="Bold">Had a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> in the past year</span></li>
<li><span class="Bold">Currently have or have had blood clots</span></li>
<li><span class="Bold">Currently have or have had liver problems</span></li>
<li><span class="Bold">Are allergic to any of the ingredients in Evamist</span></li>
</ul>
<p>See the list of ingredients in Evamist at the end of this leaflet</p>
<ul><li><span class="Bold">Think you may be pregnant</span></li></ul>
<p><span class="Bold">Tell your healthcare provider:</span></p>
<ul><li><span class="Bold">If you are breastfeeding</span></li></ul>
<p>The hormone in Evamist can pass into your breast milk.</p>
<ul><li><span class="Bold">About all your medical problems</span></li></ul>
<p>Your healthcare provider may need to check you more carefully if you have 
certain conditions, such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> (<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>), <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>), <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, 
<span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span>, lupus, or problems with your heart, liver, thyroid, kidneys, or 
have high calcium levels in your blood.</p>
<ul><li><span class="Bold">About all the medicines you take</span></li></ul>
<p>This includes prescription and nonprescription medicines, vitamins, and 
herbal supplements. Some medicines may affect how Evamist works. Evamist may 
also affect how your other medicines work.</p>
<ul><li><span class="Bold">If you are going to have surgery or will be on bed 
rest</span></li></ul>
<p>You may need to stop taking estrogens.</p>
<p><span class="Bold">How should I use Evamist?</span></p>
<a name="i4b8ad07b-b466-47bf-8fb5-78b5dbba0ff4"></a><table width="100%"><tbody class="Headless">
<tr class="First"><td>Evamist is available in a spray applicator that delivers a measured amount of 
estradiol to the skin with each spray (see <a href="#f03">Illustration 1</a>).</td></tr>
<tr><td><img alt="illustration 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d8c4a929-c039-4c7d-a3bc-986ae31fc8a6&amp;name=evamist-03.jpg"></td></tr>
<tr><td><span class="Bold">Illustration 1</span></td></tr>
<tr><td>
<p class="First">It is important that you read and follow these directions on how to use 
Evamist properly.</p>
<ul><li>Before using the applicator for the first time, it must be primed. With the 
cover on, and the applicator upright, fully depress the applicator three times 
with your thumb or index finger. This is called priming (see <a href="#f04">Illustration 2</a>). After priming, the applicator is ready to use. 
The applicator should be primed only once when you first start using a new 
applicator. DO NOT PRIME THE APPLICATOR BEFORE EACH DAY'S DOSE. </li></ul>
</td></tr>
<tr><td><img alt="illustration 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d8c4a929-c039-4c7d-a3bc-986ae31fc8a6&amp;name=evamist-04.jpg"></td></tr>
<tr><td><span class="Bold">Illustration 2</span></td></tr>
<tr><td><ul>
<li>Apply Evamist at the same time each day. </li>
<li>Apply your daily dose of Evamist to clean, dry, unbroken skin on the inside 
of the forearm between the elbow and the wrist (see <a href="#f05">Illustration 
3</a>). Do not apply Evamist to other areas of the skin. To apply the dose, 
remove the plastic cover, hold the applicator upright and rest the plastic cone 
flat against the skin. You may need to change the position of your arm or the 
position of the cone on your arm so that the cone is flat against your skin and 
there are no gaps between the cone and your skin. Depress the pump fully once. </li>
</ul></td></tr>
<tr><td><img alt="illustration 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d8c4a929-c039-4c7d-a3bc-986ae31fc8a6&amp;name=evamist-05.jpg"></td></tr>
<tr><td><span class="Bold">Illustration 3</span></td></tr>
<tr><td><ul><li>If your healthcare provider tells you to increase the dose to 2 or 3 sprays, you 
should move the cone before applying the second or third spray to an area of the 
skin next to but not touching the area of the previous spray (see <a href="#f06">Illustration 4</a>). </li></ul></td></tr>
<tr><td><img alt="illustration 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d8c4a929-c039-4c7d-a3bc-986ae31fc8a6&amp;name=evamist-06.jpg"></td></tr>
<tr><td><span class="Bold">Illustration 4</span></td></tr>
<tr class="Last"><td><ul>
<li>Always place the protective cover back on the cone of the applicator. </li>
<li>Do not massage or rub Evamist into the skin. Simply allow the spray to dry 
for at least 2 minutes before dressing, and at least 30 minutes before washing. 
</li>
<li>Evamist contains alcohol, and alcohol-based liquids are flammable. Avoid 
fire, flame or smoking when using Evamist until the spray has dried. Do not 
apply Evamist while standing near a flame. </li>
<li>Never apply Evamist directly to the breast or in or around the vagina. </li>
</ul></td></tr>
</tbody></table>
<p>Start at the lowest dose (1 spray) and talk to your healthcare provider about 
how well that dose is working for you. Treatment with estrogen should be started 
at the lowest dose possible, and used only for as long as needed to provide 
relief of moderate to severe <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span> associated with <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>. You and your 
healthcare provider should talk regularly (every 3-6 months) about the dose you 
are taking and whether you still need treatment with Evamist.</p>
<p>The Evamist applicator contains enough product to allow for initial priming 
of the pump with three sprays plus application for 75 sprays. The product will 
last approximately 75 days if you use 1 spray each day, 37 days if you use 2 
sprays each day and 25 days if you use 3 sprays each day.</p>
<p>Do not use this applicator for more than 75 sprays even though the bottle may 
not be completely empty.</p>
<p>Evamist can be stored in a clean, dry place at room temperature (15° to 30°C 
or 59° to 86°F) and does not need refrigeration. Do not freeze. Evamist should 
not be used after the expiration date. When the applicator has been used for 75 
sprays you can discard it in normal household waste.</p>
<p><span class="Bold">What should I do if I miss a dose?</span></p>
<p>If you miss a dose, do not double the dose on the next day to catch up. If 
your next dose is less than 12 hours away, it is best just to wait and apply 
your normal dose the next day. If it is more than 12 hours until the next dose, 
apply the dose you missed and resume your normal dosing the next day.</p>
<p><span class="Bold">What should I avoid while using Evamist?</span></p>
<ul>
<li>Do not allow others to make contact with the area of skin where you applied 
the spray for at least 30 minutes after application. </li>
<li>Evamist contains alcohol and alcohol-based liquids are flammable. Avoid 
fire, flame or smoking until the spray has dried. </li>
</ul>
<p><span class="Bold">What are the possible side effects of estrogens?</span></p>
<p>Side effects are grouped by how serious they are and how often they happen 
when you are treated.</p>
<p>Serious but less common side effects include:</p>
<ul>
<li>Breast cancer </li>
<li>Cancer of the uterus </li>
<li><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Heart attack</span> </li>
<li>Blood clots </li>
<li><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> </li>
<li><span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder disease</span> </li>
<li>Ovarian cancer </li>
<li>High blood pressure </li>
<li>Liver problems </li>
<li>High blood sugar </li>
<li>Enlargement of benign tumors of the uterus (“fibroids?) </li>
</ul> Some of the warning signs of these serious side effects include: 
<ul>
<li><span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">Breast lumps</span> </li>
<li>Unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and faintness </li>
<li>Changes in speech </li>
<li>Severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> </li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span> </li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Shortness of breath</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pains</span> in your legs </li>
<li>Changes in vision </li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </li>
<li>Yellowing of the skin, eyes or nail beds </li>
</ul> Call your healthcare provider right away if you get any of these warning 
signs, or any other unusual symptoms that concern you. <p>Less serious but common side effects include:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </li>
<li><span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast pain</span> </li>
<li>Irregular <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> or spotting </li>
<li>Stomach/<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span> </li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> </li>
<li><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Hair loss</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> </li>
<li>Vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span> </li>
</ul>
<p>These are not all of the possible side effects of Evamist. For more 
information, ask your healthcare provider or pharmacist.</p>
<p><span class="Bold">What can I do to lower my chances of a serious side effect 
with Evamist?</span></p>
<ul>
<li>Talk with your healthcare provider regularly about whether you should 
continue using Evamist. </li>
<li>If you have a uterus, talk with your healthcare provider about whether the 
addition of a progestin (a different prescribed hormone medication) is right for 
you. The addition of a progestin is generally recommended for women with a 
uterus to reduce the chance of getting cancer of the uterus. </li>
<li>See your healthcare provider right away if you get <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> while 
using Evamist. </li>
<li>Have a pelvic exam, breast exam, and mammogram (breast X-ray) every year 
unless your healthcare provider tells you otherwise. If members of your family 
have had breast cancer or if you have had <span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">breast lumps</span> or an abnormal mammogram, 
you may need to have breast exams more often. </li>
<li>If you have high blood pressure, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (fat in the blood), 
<span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, are overweight, or if you use tobacco, you may have a higher chance of 
getting heart disease. Ask your healthcare provider for ways to lower your 
chances of getting heart disease. </li>
</ul>
<p><span class="Bold">General information about the safe and effective use of 
Evamist.</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in 
patient information leaflets. Do not use Evamist for conditions for which it was 
not prescribed. Do not give Evamist to other people, even if they have the same 
symptoms you have. It may harm them.</p>
<p><span class="Bold">Keep Evamist out of the reach of children.</span></p>
<p>This leaflet provides a summary of the most important information about 
Evamist. If you would like more information, talk with your healthcare provider 
or pharmacist. You can ask for information about Evamist that is written for 
health professionals.</p>
<p>You can get more information by calling the toll free number (877) 
567-7676.</p>
<p><span class="Bold">What are the ingredients in Evamist?</span></p>
<p>Active ingredient: estradiol (an estrogen hormone)</p>
<p>Inactive ingredients: octisalate (a common active ingredient in some 
sunscreens used to enhance skin penetration), alcohol (to dissolve the drug)</p>
<p>Manufactured by <br>DPT <br>San Antonio, TX 78215</p>
<p>for <br>Ther-Rx Corporation <br>St. Louis, MO 63044</p>
<p><span class="Bold">Relabeling of "Additional Barcode Label" by:</span><br>Physicians Total Care, Inc.<br>Tulsa, OK       74146<br></p>
<span class="Bold"><a href="#section-"></a><a href="#section-"></a></span><div class="Section" data-sectionCode="42229-5">
<a name="section-17.1"></a><p></p>
<p class="First"><span class="Bold">Evamist (estradiol transdermal spray) 
Applicator</span></p>
<p><span class="Bold">Evamist</span></p>
<p><span class="Italics">(estradiol transdermal spray)</span></p>
<p><span class="Bold">For Topical Use Only</span></p>
<p>Metered-dose pump delivers<br>75 sprays. Each spray<br>contains 1.53 mg of 
estradiol.</p>
<p>See Patient Leaflet for<br>dosing information.</p>
<p><span class="Bold">Important: </span>Applicator<br>not child resistant.<br>Keep 
out of the reach of children.</p>
<p><span class="Bold">Flammable: </span>Avoid<br>fire, flame, or smoking during 
use.</p>
<p>Store at room temperature<br>15° to 30°C(59° to 86°F).</p>
<p>Do not freeze.</p>
<p>Rx Only 0.27 fl oz. (8.1 mL)</p>
<p>Marketed by Ther-Rx Corporation<br>St. Louis, Mo 63044 P6000 07/09</p>
<p><img alt="illustration 5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d8c4a929-c039-4c7d-a3bc-986ae31fc8a6&amp;name=evamist-07.jpg"></p>
<p><span class="Bold">Evamist (estradiol transdermal spray) Applicator 
Dust Cover</span></p>
<p><span class="Bold">Evamist</span></p>
<p><span class="Italics">(estradiol transdermal spray)</span></p>
<p>P6004 07/09</p>
<p><img alt="illustration 6" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d8c4a929-c039-4c7d-a3bc-986ae31fc8a6&amp;name=evamist-10.jpg"></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">Evamist</span></p>
<p><span class="Italics">(estradiol transdermal spray)</span></p>
<p>One spray contains 1.53 mg of estradiol</p>
<p>0.27 fl oz. (8.1 mL) <br></p>
<p>Rx Only</p>
<p><br><img alt="image of package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d8c4a929-c039-4c7d-a3bc-986ae31fc8a6&amp;name=package%20label.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>EVAMIST 		
					</strong><br><span class="contentTableReg">estradiol spray, metered</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6157(NDC:64011-215-41)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TRANSDERMAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESTRADIOL</strong> (ESTRADIOL) </td>
<td class="formItem">ESTRADIOL</td>
<td class="formItem">1.53 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>OCTISALATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6157-0</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">75  in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022014</td>
<td class="formItem">08/23/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>978cf43f-09f5-45f1-84e4-27caa1fda33a</div>
<div>Set id: d8c4a929-c039-4c7d-a3bc-986ae31fc8a6</div>
<div>Version: 1</div>
<div>Effective Time: 20100824</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
